South Korea
· Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 3.63 trillion. The enterprise value is 4.04 trillion.
| Market Cap | 3.63T |
| Enterprise Value | 4.04T |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Jun 27, 2025 |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 22.14% |
| Float | 6.20M |
Valuation Ratios
The trailing PE ratio is 33.30 and the forward PE ratio is 22.61. Hanmi Pharm.'s PEG ratio is 1.54.
| PE Ratio | 33.30 |
| Forward PE | 22.61 |
| PS Ratio | 2.45 |
| PB Ratio | 2.86 |
| P/TBV Ratio | 3.40 |
| P/FCF Ratio | 32.62 |
| P/OCF Ratio | 24.99 |
| PEG Ratio | 1.54 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.80, with an EV/FCF ratio of 36.30.
| EV / Earnings | 37.05 |
| EV / Sales | 2.72 |
| EV / EBITDA | 13.80 |
| EV / EBIT | 20.71 |
| EV / FCF | 36.30 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.16 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.62 |
| Debt / FCF | 4.25 |
| Interest Coverage | 8.50 |
Financial Efficiency
Return on equity (ROE) is 10.01% and return on invested capital (ROIC) is 7.01%.
| Return on Equity (ROE) | 10.01% |
| Return on Assets (ROA) | 6.16% |
| Return on Invested Capital (ROIC) | 7.01% |
| Return on Capital Employed (ROCE) | 14.32% |
| Revenue Per Employee | 636.38M |
| Profits Per Employee | 46.75M |
| Employee Count | 2,330 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 2.39 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 27.57 billion in taxes.
| Income Tax | 27.57B |
| Effective Tax Rate | 18.44% |
Stock Price Statistics
The stock price has increased by +4.51% in the last 52 weeks. The beta is 0.69, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +4.51% |
| 50-Day Moving Average | 279,320.00 |
| 200-Day Moving Average | 280,170.00 |
| Relative Strength Index (RSI) | 47.89 |
| Average Volume (20 Days) | 100,732 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.48 trillion and earned 108.92 billion in profits. Earnings per share was 8,589.65.
| Revenue | 1.48T |
| Gross Profit | 804.14B |
| Operating Income | 194.89B |
| Pretax Income | 149.46B |
| Net Income | 108.92B |
| EBITDA | 292.49B |
| EBIT | 194.89B |
| Earnings Per Share (EPS) | 8,589.65 |
Balance Sheet
The company has 218.53 billion in cash and 472.39 billion in debt, giving a net cash position of -253.86 billion or -20,020.02 per share.
| Cash & Cash Equivalents | 218.53B |
| Total Debt | 472.39B |
| Net Cash | -253.86B |
| Net Cash Per Share | -20,020.02 |
| Equity (Book Value) | 1.27T |
| Book Value Per Share | 87,879.22 |
| Working Capital | 97.54B |
Cash Flow
In the last 12 months, operating cash flow was 145.11 billion and capital expenditures -33.94 billion, giving a free cash flow of 111.17 billion.
| Operating Cash Flow | 145.11B |
| Capital Expenditures | -33.94B |
| Free Cash Flow | 111.17B |
| FCF Per Share | 8,767.49 |
Margins
Gross margin is 54.23%, with operating and profit margins of 13.14% and 7.35%.
| Gross Margin | 54.23% |
| Operating Margin | 13.14% |
| Pretax Margin | 10.08% |
| Profit Margin | 7.35% |
| EBITDA Margin | 19.73% |
| EBIT Margin | 13.14% |
| FCF Margin | 7.50% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.43%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.43% |
| Dividend Growth (YoY) | 66.67% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 26.67% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 0.50% |
| Earnings Yield | 3.00% |
| FCF Yield | 3.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 4.72 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.72 |
| Piotroski F-Score | 5 |